Bone health management in men undergoing ADT: examining enablers and barriers to care
- PMID: 25526712
- DOI: 10.1007/s00198-014-2997-6
Bone health management in men undergoing ADT: examining enablers and barriers to care
Abstract
The study determined prostate cancer specialists' knowledge and concordance to guidelines regarding the diagnosis, management, and prevention of androgen deprivation therapy-induced osteoporosis. Despite high knowledge regarding bone health, most respondents did not routinely measure bone mineral density or use fracture risk assessment tools, suggesting a significant gap in the screening/monitoring of bone health.
Introduction: The purpose of this study was to determine prostate cancer specialists' knowledge, practices, self-perceived competencies and barriers to providing guideline-concordant care in the diagnosis, prevention, and management of androgen deprivation therapy (ADT)-induced osteoporosis (OP).
Methods: A number of 73 Canadian radiation oncologists and 83 urologists completed questionnaires assessing (i) knowledge regarding OP and consensus guidelines for bone health management in men receiving ADT, (ii) self-assessed competencies regarding bone health management, (iii) current practices regarding OP prevention and management, and (iv) self-perceived barriers to providing guideline-concordant care.
Results: The majority of respondents were able to correctly identify the guideline-concordant frequency of repeat dual-energy X-Ray absorptiometry (DXA) scans (76.3%), vitamin D (70.3%), and calcium (53.2%) intake and that bisphosphonates/denosumab should always be considered for patients with a history of one low-trauma fracture (57.6%). Just under 1/3 (32.5%) reported routinely measuring bone mineral density (BMD) prior to starting ADT and routinely measuring BMD 1-2 years following the initiation of ADT (36.6%). Only 4.6% of respondents routinely used a validated fracture risk assessment tool. Lowest self-assessed competency levels were reported in providing self-management education to patients to foster the uptake of healthy bone behaviors (HBBs) and managing patients who present with or develop osteopenia and OP. The most significant barriers to providing OP prevention and management were lack of time and lack of supporting structures.
Conclusions: Despite high knowledge about appropriate bone health care among prostate cancer specialists, there remain significant gaps in screening and monitoring of bone health, suggesting the need to develop innovative strategies to overcome barriers to implementation.
Similar articles
-
Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer.BJU Int. 2013 Jun;111(8):1301-9. doi: 10.1111/j.1464-410X.2012.11777.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23351062
-
Management of osteoporosis in men on androgen deprivation therapy.Maturitas. 2011 Feb;68(2):143-7. doi: 10.1016/j.maturitas.2010.11.003. Epub 2010 Dec 3. Maturitas. 2011. PMID: 21129866 Review.
-
Bone health management in prostate cancer patients receiving androgen deprivation therapy.J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1. J Oncol Pharm Pract. 2012. PMID: 21807761
-
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.Cancer. 2004 Mar 1;100(5):892-9. doi: 10.1002/cncr.20056. Cancer. 2004. PMID: 14983482 Review.
-
Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.Med J Aust. 2011 Mar 21;194(6):301-6. doi: 10.5694/j.1326-5377.2011.tb02979.x. Med J Aust. 2011. PMID: 21426285 Review.
Cited by
-
Adverse bone effects of medications used to treat non-skeletal disorders.Osteoporos Int. 2017 Oct;28(10):2741-2746. doi: 10.1007/s00198-017-4171-4. Epub 2017 Jul 27. Osteoporos Int. 2017. PMID: 28752332 Review.
-
The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.Oncotarget. 2017 May 18;8(43):75646-75663. doi: 10.18632/oncotarget.17980. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088899 Free PMC article. Review.
-
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.Osteoporos Int. 2017 May;28(5):1507-1529. doi: 10.1007/s00198-016-3894-y. Epub 2017 Feb 7. Osteoporos Int. 2017. PMID: 28175979 Free PMC article. Review.
-
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.J Bone Oncol. 2020 Aug 2;25:100311. doi: 10.1016/j.jbo.2020.100311. eCollection 2020 Dec. J Bone Oncol. 2020. PMID: 32995252 Free PMC article.
-
Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.Prostate Cancer Prostatic Dis. 2018 Nov;21(4):461-472. doi: 10.1038/s41391-018-0060-y. Epub 2018 Jul 9. Prostate Cancer Prostatic Dis. 2018. PMID: 29988100 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous